siRNA for treating hbv

A technology for HBV and treatment, applied in the field of genetic engineering, can solve the problems of chronic HBV patients obtaining expected results and being in a state of immune tolerance
CN102533768BInactive Publication Date: 2013-03-27SHANDONG UNIV
3 Cites 0 Cited by

Patent Information

Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
SHANDONG UNIV
Publication Date
2013-03-27
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention discloses siRNA (small interfering RNA) for treating HBV (hepatitis B virus), which has a sequence shown in SEQ ID NO.3. The siRNA can be artificially synthesized or synthesized through in vivo transcription. After the siRNA transfects HepG2.2.15 cell for 24 hours and 48 hours, the siRNA can reduce the expression of HBx gene, the content of HBsAg and HBeAg in the cell and supernate is also obviously reduced, and the effect of 3p-siRNA is more obvious than that of chemically synthesized siRNA. The siRNA can be applied to medicaments for resisting the HBV.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention relates to a siRNA used for treating HBV, which belongs to the field of genetic engineering. Background technique

[0002] At present, there are about 420 million HBV carriers in the world, and HBV infection is one of the diseases that seriously affect human health. Chronic HBV infection is closely related to the occurrence of liver fibrosis and liver cancer. However, most of the chronic HBV patients did not get the expected results under conventional treatment. Although interferon can inhibit the replication of HBV, HBV can resist the anti-virus mechanism of the body by inhibiting the secretion and function of interferon, and finally lead the body to a state of immune tolerance. For example, in the peripheral blood and liver infiltrating cells of patients with chronic infection, the proportion of regulatory T cells was significantly increased. In addition, HBsAg, HBeAg, and other viral agents can directly suppress TLR-mediated innate ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More